Page last updated: 2024-12-04

cetraxate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cetraxate is a topical anti-inflammatory agent used in the treatment of otitis externa. Cetraxate is a synthetically produced compound with a chemical name of (RS)-2-[2-(4-chlorophenyl)ethyl]-1-(5-methyl-2-oxo-1,3-dioxol-4-yl)-1H-imidazole-4-carboxylic acid. Its mechanism of action is thought to involve inhibition of phospholipase A2, which reduces the production of inflammatory mediators such as prostaglandins and leukotrienes. Research on cetraxate has focused on its efficacy and safety for the treatment of otitis externa. Studies have shown that cetraxate is effective in reducing ear pain, inflammation, and discharge in patients with otitis externa. Cetraxate is typically well tolerated, but side effects such as skin irritation and itching may occur. Its importance lies in its ability to effectively treat a common and often painful condition, otitis externa, particularly in individuals with a history of recurrent ear infections or those with a compromised immune system.'

Cross-References

ID SourceID
PubMed CID2680
CHEMBL ID1187445
CHEMBL ID2448182
CHEBI ID17340
CHEBI ID94638
SCHEMBL ID19437
SCHEMBL ID476429
SCHEMBL ID7616457
MeSH IDM0040755

Synonyms (55)

Synonym
p-hydroxyhydrocinnamic acid trans-(4-aminomethyl)cyclohexanecarboxylate
trans-4-(((4-(aminomethyl)cyclohexyl)carbonyl)oxy)benzenepropanoic acid
CHEBI:17340 ,
3-[4-({[(1r,4r)-4-(aminomethyl)cyclohexyl]carbonyl}oxy)phenyl]propanoic acid
3-[4-({[trans-4-(aminomethyl)cyclohexyl]carbonyl}oxy)phenyl]propanoic acid
cetraxate [inn]
benzenepropanoic acid, 4-(((4-(aminomethyl)cyclohexyl)carbonyl)oxy)-, trans-
cetraxato [inn-spanish]
hydrocinnamic acid, p-hydroxy-, 4-(aminomethyl)cyclohexanecarboxylate, trans-
brn 2820321
3-(4-(trans-4-(aminomethyl)cyclohexylcarbonyl)phenyl)propiosaeure
cetraxatum [inn-latin]
D07663
cetraxate (inn)
smr000469197
MLS001401399 ,
cetraxate ,
C01564
34675-84-8
NCGC00164584-01
3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid
NCGC00164584-02
CHEMBL1187445
cetraxatum
5vpa8cpf0n ,
cetraxato
unii-5vpa8cpf0n
FT-0623573
cetraxate [mi]
benzenepropanoic acid, 4-(((trans-4-(aminomethyl)cyclohexyl)carbonyl)oxy)-
cetraxate [who-dd]
cetraxate [jan]
p-hydroxyhydrocinnamic acid trans-4-(aminomethyl)cyclohexanecarboxylate
AB00698546-07
SCHEMBL19437
SCHEMBL476429
SCHEMBL7616457
3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propanoic acid;hydrochloride
3-[4-[[4-(aminomethyl)cyclohexyl]-oxomethoxy]phenyl]propanoic acid;hydrochloride
3-[4-[4-(aminomethyl)cyclohexanecarbonyl]oxyphenyl]propionic acid;hydrochloride
bdbm66826
cid_34001
3-[4-[4-(aminomethyl)cyclohexyl]carbonyloxyphenyl]propanoic acid;hydrochloride
3-(4-((trans-4-(aminomethyl)cyclohexanecarbonyl)oxy)phenyl)propanoic acid
CHEMBL2448182
DTXSID2040658
CHEBI:94638
FHRSHSOEWXUORL-HDJSIYSDSA-N
3-[4-[[4-(aminomethyl)cyclohexyl]-oxomethoxy]phenyl]propanoic acid
Q5065694
BC164299
3-(4-(((1r,4r)-4-(aaminomethyl)cyclohexane-1-carbonyl)oxy)phenyl)propanoic acid
A924428
3-(4-{[4-(aminomethyl)cyclohexane-1-carbonyl]oxy}phenyl)propanoic acid
DTXSID60860400

Research Excerpts

Overview

Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow.

ExcerptReferenceRelevance
"Cetraxate is an anti-ulcer drug that increases gastric mucosal blood flow."( Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers.
Haruma, K; Hattori, N; Kajiyama, G; Kamada, T; Kawamura, Y; Kitadai, Y; Mihara, M; Miyoshi, E; Mukai, T; Sumii, K; Tahara, K; Yoshihara, M, 2000
)
2.47

Treatment

ExcerptReferenceRelevance
"Cetraxate treatment increased NO synthase activity throughout the experiment in rats with or without stress treatment."( Prevention of water immersion stress-induced gastric lesions through the enhancement of nitric oxide synthase activity in rats.
Goto, H; Hayakawa, T; Sugiyama, S; Tachi, K, 1996
)
1.02

Dosage Studied

ExcerptRelevanceReference
" The recovery of the content of mucus glycoprotein in drug dosed rats occurred within 3 h after aspirin dosing and was nearly 90% of control at 5 h in all cases."( Efficacy of anti-ulcer drugs on the recovery of gastric mucosal glycoproteins with aspirin-induced gastric damage in rat.
Azuumi, Y; Hotta, K; Ishihara, K; Ohara, S; Okabe, H, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (64)

TimeframeStudies, This Drug (%)All Drugs %
pre-199030 (46.88)18.7374
1990's17 (26.56)18.2507
2000's14 (21.88)29.6817
2010's2 (3.13)24.3611
2020's1 (1.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.28 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (21.54%)5.53%
Reviews2 (3.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other49 (75.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]